Literature DB >> 15788803

Smoking attributable mortality in the community of Madrid: 1992-1998.

Belén Zorrilla-Torras1, Natividad García-Marín, Iñaki Galán-Labaca, Ana Gandarillas-Grande.   

Abstract

BACKGROUND: The proportion of smokers and the number of cigarettes consumed per person-year in Madrid is above the European average. To evaluate the impact of smoking in public health smoking attributable mortality was estimated for 1998 and for changes since 1992.
METHODS: The number of smoking attributable deaths and years of potential life lost attributable to cigarette smoking for 1992 and 1998 by gender and age group were estimated, based on the population attributable fraction. The relative risks of the Cancer Prevention Study II were used. To compare the two periods of study, a Poisson regression analysis adjusted by age was applied.
RESULTS: In 1998, 15.9% of total mortality in the population older than 34 years was attributable to smoking. Lung cancer and chronic obstructive pulmonary disease are the main causes of death in both genders. In the period studied, 1992-1998, the adjusted rates diminished in men in both age groups, while in women they increased in the age group 35 to 64 years. The mortality from lung cancer remained stable in men, increasing in women by 12%. The years of potential life lost decreased by 14% in men and increased by 42% in women.
CONCLUSIONS: One in four deaths in men and one in 36 deaths in women are attributed to cigarette smoking. The smoking attributable mortality in males has tended to stabilize, while in women premature mortality is increasing. KEY POINTS: Smoking attributable mortality was estimated for 1998 and for changes since 1992 to evaluate the impact of smoking in the population older than 34 years. MAIN
RESULTS: In the period studied, 1992-1998, the adjusted mortality rates attributable to smoking diminished in men, while in women they increased in the age group 35 to 64 years. The main causes of Smoking attributable mortality are Lung cancer and chronic obstructive pulmonary disease in both genders. The mortality from lung cancer remained stable in men, increasing in women by 12%. IMPLICATIONS FOR PUBLIC HEALTH: In the Community of Madrid, health promotion programmes to reduce cigarette smoking need to be intensified, specially in women.

Entities:  

Mesh:

Year:  2005        PMID: 15788803     DOI: 10.1093/eurpub/cki110

Source DB:  PubMed          Journal:  Eur J Public Health        ISSN: 1101-1262            Impact factor:   3.367


  6 in total

1.  Estimates of smoking-attributable mortality and hospitalization in BC, 2002-2007.

Authors:  Andrew W Tu; Jane A Buxton; Tim Stockwell
Journal:  Can J Public Health       Date:  2012 Mar-Apr

2.  Female smokers beyond the perimenopausal period are at increased risk of chronic obstructive pulmonary disease: a systematic review and meta-analysis.

Authors:  Wen Qi Gan; S F Paul Man; Dirkje S Postma; Patricia Camp; Don D Sin
Journal:  Respir Res       Date:  2006-03-29

3.  The impact of life tables adjusted for smoking on the socio-economic difference in net survival for laryngeal and lung cancer.

Authors:  L Ellis; M P Coleman; B Rachet
Journal:  Br J Cancer       Date:  2014-05-22       Impact factor: 7.640

4.  Smoking-attributable mortality in Morocco: results of a prevalence-based study in Casablanca.

Authors:  Nabil Tachfouti; Chantal Raherison; Adil Najdi; Majdouline Obtel; Ahmed Rguig; Amina Idrissi Azami; Chakib Nejjari
Journal:  Arch Public Health       Date:  2014-07-01

5.  Higher risk of wheeze in female than male smokers. Results from the Swedish GA 2 LEN study.

Authors:  Anders Bjerg; Linda Ekerljung; Jonas Eriksson; Inga Sif Ólafsdóttir; Roelinde Middelveld; Karl A Franklin; Bertil Forsberg; Kjell Larsson; Jan Lötvall; Kjell Torén; Sven-Erik Dahlén; Bo Lundbäck; Christer Janson
Journal:  PLoS One       Date:  2013-01-24       Impact factor: 3.240

6.  Smoking-attributable mortality and years of potential life lost in 16 Brazilian capitals, 2003: a prevalence-based study.

Authors:  Paulo C R P Corrêa; Sandhi M Barreto; Valéria M A Passos
Journal:  BMC Public Health       Date:  2009-06-26       Impact factor: 3.295

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.